• Samsung Biologics set an initial issue price of KRW 1,174,000 per common share for a paid-in capital increase.
• Final pricing due Nov. 5, 2026, based on the lower of two discounted reference-price calculations, subject to a 40% discount floor.
• The pricing formulas apply a 15% discount rate, with adjustments for the capital increase ratio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001800318), on October 01, 2026, and is solely responsible for the information contained therein.